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Purpose: To identify sequence variants of the ataxia telangiectasia mutated (ATM ) gene
and establish their prevalence rate among American Indian (AI) as compared with non-AI
cancer patients.
Materials and Methods: DNA was isolated from blood samples collected from 100 AI and
100 non-AI cancer patients undergoing radiation therapy, and a blinded assessment of the
ATM sequence was conducted. Quantitative PCR assessment of copy number for each
exon was also performed.The main outcome measure was the prevalence of ATM variants
in the two patient populations.
Results: No statistically significant differences for total prevalence of ATM variants among
AI and non-AI patients were found. Of the 25 variants identified, 5 variants had a prevalence
of >2%, of which 4 occurred at a rate of >5% in one or both groups. The prevalence of
these four variants could meaningfully be compared between the two groups. The only
statistically significant difference among the groups was the c.4138C>T variant which is
predicted not to affect protein function, seen in 8% of AI versus 0% of non-AI patients
(P =0.007). No exonic copy number changes were found in these patients.
Conclusion: This study is the first to determine the prevalence of ATM variants in AIs.
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INTRODUCTION
Radiation has a pivotal role in the management of human can-
cer with approximately 50% of all cancer patients receiving it at
some point during their course of treatment. While radiation ther-
apy is often successful in the local eradication of tumor cells, late
normal tissue effects may significantly reduce organ function and
health-related quality of life in a proportion of long term can-
cer survivors (1). Individual variability in normal tissue response
to fractionated radiotherapy has been observed in both clinical
and laboratory studies. The risk of radiation induced toxicities is
affected by treatment related factors such as total radiation dose,
dose per fraction, volume of normal tissue irradiated, and other
patient related factors (2, 3). These factors alone are not sufficient
to account for the variability seen among patients, however. Hence,
identifying new genetic biomarkers having potential relevance to
toxicities and incorporating these into traditionally used assess-
ment tools will help personalize treatment plans and potentially
increase efficacy and reduce toxicities.
The induction and processing of radiation damage to normal
cells and tissues involve multiple molecular pathways from DNA
damage repair to wound healing responses and tissue remodeling
(4). Genetic variability in genes that regulate these processes can
either play a protective role or render an individual susceptible
to radiation induced cell damage. Ataxia telangiectasia mutated
(ATM) is a serine threonine kinase that phosphorylates several
substrates involved in diverse functions such as repair of double
stranded breaks in DNA, cell cycle regulation, radiosensitivity, and
oxidative stress. A-T is an autosomal recessive disorder and is a
result of deleterious mutation in the ATM gene (5). Typical mani-
festations are neurological deterioration and ocular telangiectasia
and increased susceptibility to radiation toxicities (6).
Skin fibroblasts from A-T patients show a threefold increase
in radiosensitivity when irradiated in vitro compared to normal
human fibroblasts (7). Although A-T homozygotes are rare, A-T
heterozygosity is estimated to occur in about 1–2% of the Cau-
casian population in the US (8). Heterozygosity for mutations
shown to result in AT may confer a greater risk of developing
cancer and increased radiosensitivity to carriers (9).
American Indians (AIs) appear more sensitive to fractionated
radiotherapy as reported by our group. This was evident by AIs
developing higher rates of G3 skin and mucosal reactions as com-
pared to non-AI patients (10). The ATM gene has not been studied
in Northern Plains AIs, a population that exhibits disproportion-
ate burden of cancer mortality. We hypothesized that a significant
proportion of AI that manifest toxicities in response to radiation
therapy carried deleterious variants in the ATM gene. In this study
we aimed to determine the prevalence of ATM variants among
AI cancer patients and compare this to non-AI cancer patients.
The ATM study is one of many conducted by our group known as
Walking Forward which has been in existence since 2002. This NCI
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funded program addresses cancer disparities through patient nav-
igation, enrollment to clinical trials, and determinants of cancer
screening and delays to cancer diagnosis and treatment (11).
MATERIALS AND METHODS
PATIENTS
Peripheral blood was obtained from 202 patients (101 AIs and
101 non-AIs) seen during a routine treatment visit or follow-up.
Patients were staged according to American Joint Committee on
Cancer standards. 10.5% of patients were treated with palliative
intent and 89.5% with curative intent. The study was approved by
the Rapid City Regional Hospital’s Institutional Review Board and
by all Tribal entities that were a part of this study. All patients who
participated were consented.
DNA EXTRACTION AND SEQUENCING
Genomic DNA was extracted from peripheral blood lympho-
cytes via the PAXgene Blood DNA Kit (Qiagen) and dissolved
into 600µl volumes of Buffer BG4 (Qiagen). The concentra-
tion of the dissolved gDNA was determined using a SpectraMax
190 Microplate Reader (Molecular Devices) or Nanodrop 1000
spectrophotometer (Thermo Scientific).
ATM EXON CHARACTERIZATION
Coding exons 4 through 65 and flanking intronic regions were
amplified individually, except for exons 4 and 5, 23 and 24, and
43 and 44 which were amplified as single products. Exon number-
ing is based on transcript NM_000051.3 as described elsewhere
(12). We used a set of primers as previously published (13) with
a few alterations. Amplification was done with the MasterTaq
kit (5′) in 20µl volumes consisting of 1× TaqMaster solution,
1.5 mM Mg2+, 0.2 mM mixed dNTP’s, 0.5 U/µl taq, 8 pmols of
sense primer, 8 pmols of anti-sense primer, and ~125 ng gDNA
in reagent grade water. Sequencing was done with the Big Dye
v3.1 solution in 10µl volumes using 4 pmol of one primer, 0.25µl
Big Dye v3.1, 3.75µl 2.5× buffer (19 mM Tris-HCl, 180 mM Tris,
5 mM MgCl2, pH 9.0± 0.5), ~1 ng DNA per 100bp of amplicon
length and reagent grade water.
Multiplex PCR was done to test the copy number of each exon.
An unrelated non-polymorphic marker on chromosome 7 was
included in each mix to serve as a non-ATM control peak. About
~125 ng gDNA was amplified with 5µl 2× Master Mix from the
Multiplex PCR kit (Qiagen), 2µl of a 0.5:50µM mix of sense to
anti-sense primers, and 1µl each of 7µM FAM- or HEX-labeled
additional universal sense primers. The sense primers for each
exon were designed to bind one of the universal sense primers.
Amplification products were diluted 1:5 with water. GeneFlo 625
DNA Markers (ChimerX) were diluted 0.3µl in 15µl distilled
water per sample. Then 1µl of diluted amplicons was mixed
with 15.3µl diluted markers, denatured at 95°C, and immediately
cooled. The products were analyzed with an ABI 3730xl DNA
analyzer.
VARIATION DISCOVERY AND CHARACTERIZATION
Traces were checked for quality, processed into a multi-alignment
assembly for each exon, and scanned for variations using visual
inspection, SequenceScanner v1.0 (Applied Biosystems), and the
Staden Package 1.6.0 for Mac and 2002 for Windows (14). Poten-
tial variants were confirmed based on sequencing in the opposite
direction and/or a second or third sequencing run. Variants were
named according to the recommendations of the Human Genome
Variation Society. PolyPhen-2 (15), a software tool that predicts the
likely impact of an amino acid substitution on the function of a
human protein, was run on each variant.
Fragment files from the exon copy number tests were down-
loaded and analyzed without additional manipulation in Peak
Scanner v1.0 (Applied Biosystems).
STATISTICS
Fisher’s Exact Test was used to test for an association between
ethnicity and prevalence of a specific genotype. Analyses were
performed using IBM SPSS version 20.0.0. Statistical significant
associations were defined as those where the two-sided P-value
was lower than or equal to 0.05. Prevalence estimates are specified
in percent together with their exact 95% confidence limits.
OBTAINING CONSENT
While there were initial concerns that this study could not be
opened, or accrued to, due to concerns of genetic testing in a dis-
parate population, IRB approval was rapidly obtained with only a
few patients refusing participation. Patients were eager to enroll as
they believed it could help the next generation of cancer patients.
RESULTS
A total of 25 variants were identified in this patient population;
6 would be predicted to be silent, and 19 would be predicted to
result in change in the protein sequence (Table 1). None would
be predicted to truncate the protein. Of those missense variants,
14 were predicted to be possibly or probably damaging to protein
function. None of the variants identified in this study have been
associated with the development of A-T. One of the variants (7228
T>C) found in one non-AI patient, was not previously registered
in the NCBI dSNP database. No statistically significant difference
for total prevalence of variants was found among AI (40%) and
non-AI (48%) patients (P = 0.32). Nineteen of the variants were
found in the non-AI patients and 12 in the AI patients. Five variants
had a prevalence of≥2%, of which four occurred at a rate of>5%
in one or both groups (Table 2). The prevalence of these could
meaningfully be compared statistically in the two groups. The
only statistically significant difference among the groups was the
c.4138C>T variant seen in 8% of AI versus 0% of non-AI patients
(P = 0.007). However, the PolyPhen-2 software tool predicts that
this variant (His1380Tyr) will not affect protein function. Also
another variant, variant c.5557G>A, had a prevalence of 25% in
non-AI versus 14% in AI patients (P = 0.07) but is predicted not
to affect protein function. Three patients are homozygous for this
variant, all in the non-AI group. There was one additional non-AI
patient who is homozygous for the c.378C>T variant which is
also predicted to be benign. The prevalence of those variants pre-
dicted to result in potentially deleterious missense mutations was
7% among non-AI and 7% among AI patients.
Sixteen patients had more than one variant, in four cases
this involved the c.4578C>T and c.5557G>A pair of variants
(Table 3). Two patients had three variants. We were unable to
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Table 1 | List of exonic variants.
cDNA-level
variation name
(based on
LRG_135)
rs No. Exon Theoretical
protein-level
variation name
PolyPhen-2a results
(humdiv-trained)
nTotal
patients
n Caucasian
patients
n Native
American
patients
Non-synonymous variants
c.[94C>T];[=] rs148061139 05 p.[(Arg32Cys)];[(=)] Probably damaging 1 1 0
c.[146C>G];[=] rs1800054 05 p.[(Ser49Cys)];[(=)] Probably damaging 1 0 1
c.[202A>G];[=] rs35389822 06 p.[(Ile68Val)];[(=)] Benign 1 1 0
c.[378T>A];[378T>A] rs2234997 07 p.[(Asp126Glu)];[(Asp126Glu)] Benign 1 1 0
c.[998C>T];[=] rs28904919 10 p.[(Ser333Phe)];[(=)] Possibly damaging 1 1 0
c.[1229T>C];[=] rs56128736 11 p.[(Val410Ala)];[(=)] Possibly damaging 2 1 1
c.[1744T>C];[=] rs2235006 13 p.[(Phe582Leu)];[(=)] Benign 1 0 1
c.[1960C>A];[=]b – 15 p.[(Gln654Lys)];[(=)] Benign 1 1 0
c.[2119T>C];[=] rs4986761 15 p.[(Ser707Pro)];[(=)] Benign 2 2 0
c.[2149C>T];[=] rs147515380 16 p.[(Arg717Trp)];[(=)] Probably damaging 1 1 0
c.[2572T>C];[=] rs1800056 19 p.[(Phe858Leu)];[(=)] Possibly damaging 1 0 1
c.[3161C>G];[=] rs1800057 24 p.[(Pro1054Arg)];[(=)] Probably damaging 4 1 3
c.[3383A>G];[=] rs56398245 25 p.[(Gln1128Arg)];[(=)] Possibly damaging 1 0 1
c.[4138C>T];[=] rs3092856 30 p.[(His1380Tyr)];[(=)] Benign 8 0 8
c.[4258C>T];[=] rs1800058 31 p.[(Leu1420Phe)];[(=)] Benign 9 7 2
c.[5071A>C];[=] rs1800059 36 p.[(Ser1691Arg)];[(=)] Benign 1 1 0
c.[5557G>A];[=] rs1801516 39 p.[(Asp1853Asn)];[(=)] Benign 36 22 14
c.[5557G>A];[5557G>A] rs1801516 39 p.[(Asp1853Asn)];[(Asp1853Asn)] Benign 3 3 0
c.[5558A>T];[=]c rs1801673 39 p.[(Asp1853Val)];[(=)] Possibly damaging 1 1 0
c.[7228T>C];[=]d rs193302874 51 p.[(Phe2410Leu)];[(=)] Probably damaging 1 1 0
Non-synonymous
variant subtotals
77 45 32
Synonymous variants
c.[162T>C];[=] rs3218690 05 (p.=) Tyr54 N/A 1 0 1
c.[657T>C];[=] rs2235003 08 (p.=) Cys219 N/A 1 1 0
c.[735C>T];[=] rs3218674 09 (p.=) Val245 N/A 2 1 1
c.[4578C>T];[=] rs1800889 32 (p.=) Pro1526 N/A 23 11 12
c.[5793T>C];[=] rs3092910 41 (p.=) Ala1931 N/A 2 2 0
c.[8592C>T];[=] rs56025670 61 (p.=) Tyr2864 N/A 1 1 0
Synonymous variant
subtotals
30 16 14
Nomenclature style is taken from the Human Genome Variation Society
recommendations, found at http://www.hgvs.org/mutnomen/
Variant totals for all 107 61 46
aPolyPhen-2 v2.2.2, updated February 15, 2012. Available from: http:// genetics.bwh.harvard.edu/ pph2/ index.shtml
bWhile not in dbSNP, this variant was noted in Ref. (16).
cThere is one Caucasian patient who had an indeterminate genotype in this codon. The patient is represented in each heterozygous category independently in this
table. c.[5557G>A (;) 5558A>T] p.[(Asp1853?)];[(?)]. Amino acid change possibilities: AAT, asparagine (polar, neutral, benign); ATT, isoleucine (non-polar, neutral,
possibly damaging); GAT, no change on one allele; GTT, valine (non-polar, neutral, possibly damaging).
dThis variant was not in any publications or in dbSNP prior to our submission.
determine the haplotype for any of the patients with multiple
variants.
We performed an analysis for exonic copy number and found
no variations in exonic copy number within this population.
DISCUSSION
As part of the original research design, the ATM gene was inves-
tigated as there was concern that the AI patient population was
more sensitive to the effects of therapeutic radiation. Fear of this
treatment related side-effect could potentially contribute to the
commonly observed treatment delays observed in this patient pop-
ulation. A total of 101 AI and 101 non-AI participated in the ATM
study (17). This study provided new information on the ethnic
distribution of ATM variants in a regional US population, and is
the first to determine the prevalence of ATM variants in AI cancer
patients.
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Table 2 | Prevalence (95% confidence limits) of most common ATM variants.
SNP American Indians Non-American Indians P -value* PolyPhen
c.5557G>A 14% (8%, 22%) 25% (17%, 35%)a 0.07 Probably benign
c.4578C>T 12% (6%, 20%) 11% (6%, 19%) 1.0 NAb
c.4258C>T 2% (0.2%, 7%) 7% (3%, 14%) 0.17 Benign
c.4138C>T 8% (4%, 15%) 0% (0%, 4%) 0.007 Benign
c.3161C>G 3% (0.6%, 9%) 1% (0.03%, 4%) 0.61 Probably damaging
Any variant 40% (30%, 50%) 48% (38%, 58%) 0.32 –
*P-value for the null hypothesis of equal prevalence in American Indians and non-American Indians patients.
aThree homozygous cases.
bSynonymous change.
Table 3 | Summary of ATM variants.
Patients with multiple variant combinations Number of
patients with
combination
c.998C>T c.5557G>A 1
c.1229T>C c.5557G>A 1
c.4578C>T c.5557G>A 4
c.378T>A c.657T>C 1
c.2119T>C c.2149C>T c.4578C>T 1
c.4258C>T c.5071A>C 1
c.4258C>T c.4578C>T 1
c.735C>T c.4258C>T 1
c.5557G>A c.5558A>T 1
c.2572T>C c.3161C>G 1
c.202A>G c.3161C>G c.5557G>A 1
c.146C>G c.5557G>A 1
c.4138C>T c.4578C>T 1
Our results indicate that the variants found in the AI patient
population, with the exception of the 4138C>T variant, are also
found in the non-AI population. In fact, there were more variants
identified in the non-AI population. The most prevalent variant
found in both populations was the 5557 G>A variant – resulting
in the replacement of aspartic acid with asparagine, a substitu-
tion that the PolyPhen-2 tool predicts to be benign. At the time
of writing, there are at least 11 published studies of the possible
link between this particular variant and normal tissue toxicity after
radiation therapy. The outcomes of these studies are inconsistent,
ranging from studies finding an increased risk of toxicity among
carriers of the minor allele to a decreased risk, and with several
studies finding no significant link. A large individual patient level
meta-analysis of all the available data is being conducted by the
international Radiogenomics Consortium (RGC), see below.
The c.5557G>A SNP has also been intensively studied with
respect to possible association with breast cancer susceptibility.
Recent meta-analyses found no evidence of such an association
(18), although interestingly in the present context, in a sub-group
analysis stratifying for ethnicity AIs did show an increased odds
ratio of 2.19 (with 95% CI 1.38–3.47). However, further studies
are needed to confirm this finding.
A recent attempt at validating a large number of SNP’s that
have previously been reported by various groups to be associated
with toxicity after radiation therapy showed that not a single one
of these could be independently validated, in other words the pub-
lished literature is dominated by false-positive associations (19). In
an attempt to synthesize information from multiple studies and
to push the number of cases in future studies into the range of
2,000–10,000 cases, an international RGC was formed in Novem-
ber 2009 (20). The RGC has more than 110 members mainly from
Asia, Europe, and North America with expertise in radiation biol-
ogy, radiation oncology, epidemiology, genetics, radiation physics,
statistics, or bioinformatics. The data from the present study are
also included in the RGC virtual databank. Relatively small stud-
ies like the present one are of great potential value as haplotypes
will tend to differ between various ethnic groups. One could envi-
sion a research strategy where the predictive strength of various
variants was established in the larger cohorts, potentially using
genome wide association methodologies (discovery phase), val-
idated in the same population whereafter the most promising
among the validated variants would subsequently be tested in pop-
ulations such as the AI. It is also possible that rare variants could
be relatively more common in some populations due to founder
mutations. However, in the present study there was no evidence of
this, with the possible exception of the c.4138C>T SNP among
the AI patients.
It was originally planned to correlate the variant data to patient
toxicity data with the hopes of finding a predictive assay. However,
the analysis was not performed because of the heterogeneity in
disease sites, and the fact that the distribution among sites were
different in the AI and non-AI groups. It is more realistic that
discovery of variants linked with toxicity will come from much
larger populations, and once strong candidate variants have been
identified the prevalence of these among the AI patients can be
established.
CONCLUSION
There is no support in our study for the hypothesis that a difference
in prevalence or type of ATM variants explains the different spec-
trum of side-effects seen after radiotherapy in AI versus non-AI
patients. Correlation to variant and toxicities was not performed
as the study was underpowered. The successful completion of this
study is indicative of the trust we have garnered with tribal entities
throughout Western SD, and has positioned us to now become
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part of the worldwide RGC, where we will help to potentially solve
the mystery of finding a predictor of increased radiosensitivity.
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